Biosimilars

Brain Cancer

HER2+ Breast Cancer

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Pediatric Oncology

Precision Medicine in Oncology®

Sarcomas

Supportive Care

Zongertinib demonstrated durable efficacy in patients with pretreated advanced HER2-mutant non–small cell lung cancer.

Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC 

Second-line lenvatinib had clinically meaningful efficacy in patients with advanced HCC after progression on atezolizumab plus bevacizumab.

Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab

The phase 3 TROPiCS-04 study missed its primary end point of improved OS with sacituzumab govitecan vs chemotherapy in patients with urothelial cancer.

Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma

Rates of invasive cancer were noninferior when patients with low-risk ductal carcinoma in situ received active monitoring vs guideline concordant care. 

Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS

News

OncClub

All Oncology News

Media

Insights

MedNews Week

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

CME/CE

Scientific Interchanges

State of the Science Summit / IPC

National Fellows Forum

Webinars

Partners

Publications

Resources

Interactive Tools

Biomarker Consortium

Subscribe

 in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Ryan Scott joined MJH Life Sciences in 2021. In addition to writing and editing timely news and article coverage, she manages 

 social media accounts; check us out @onclive across platforms such as LinkedIn, Facebook, X, and Instagram! She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: 

Adding dostarlimab to chemotherapy and niraparib maintenance improved progression-free survival in first-line advanced ovarian cancer.

Addition of Dostarlimab to Chemo and Niraparib Maintenance Boosts PFS in Advanced Ovarian Cancer

 as an assistant editor in October 2022. Leveraging an educational background in the life sciences and prior experience conducting interviews in a university setting, she plays a key role in shaping social media strategy, covering live conferences, and producing multimedia content for both print and digital platforms. Email: 

The addition of pegcrisantaspase to venetoclax may overcome resistance to prior BCL-2 inhibitor–based regimens for patients with relapsed/refractory AML. 

Venetoclax Plus PegC May Overcome Resistance to Prior BCL-2 Inhibitors in R/R AML 

The FDA has approved encorafenib plus cetuximab and mFOLFOX6 for metastatic colorectal cancer with a BRAF V600E mutation.

FDA Grants Accelerated Approval to Encorafenib Plus Cetuximab and Chemo for BRAF V600E+ Metastatic Colorectal Cancer  

Megan Hollasch joined MJH Life Sciences in 2022 following graduation from the University of Massachusetts Amherst with majors in Communication and English, and a specialization in Literature as History. She produces and edits original content for the print publication 

, aiding in all aspects of the publication process, as well as content for OncLive.com.

Retifanlimab represents a promising agent in the squamous cell anal carcinoma field and additional research is needed to improve outcomes for patients.

Filling Unmet Needs in SCAC Is Key as Incidence Rates Are Rising 

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

MJH Life Sciences brands

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Updates in the Management of Stage III Non-Small Cell Lung Cancer (NSCLC)

Management of Resectable Early Stage NSCLC with Actionable Mutations

Video content above is prompted by the following:

How does your approach differ based on PD-L1 status? Presence of EGFR/ALK alterations?

Videos

Led by Sandip P. Patel, MD, key opinion leaders address key updates in treatment strategies and management of stage III NSCLC.

Medical experts discuss a specific case for a patient diagnosed with stage IIIB NSCLC.

Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

Panelists discuss the utilization of testing and multidisciplinary approaches for testing.

Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

The panel discusses a variety of clinical trials and the impact on patient treatment in early stage NSCLC.

Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

A variety of treatment options in ES NSCLC are explored by key opinion leaders.

Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC 

The panel discusses reassessing for respectability after certain treatments.

Management of Borderline Resectable NSCLC

The panel discusses management of resectable early-stage non–small cell lung cancer.

The panel discusses the factors that go into selecting patients for adjuvant therapy.

Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

The panel looks at a second patient case study.

Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease 

The panel discusses data necessary for selecting patients with unrespectable non–small cell lung cancer for sequential vs concurrent chemoradiotherapy.

Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

The panel discusses treatment considerations for consolidation durvalumab.

Management of Resectable Early Stage NSCLC with Actionable Mutations

EP: 1.Patient with Stage IIIB NSCLC with No Actionable Mutations and PD-L1 TPS 0%

EP: 2.Biomarker Testing and the Multidisciplinary Approach in Early-Stage NSCLC

EP: 3.Navigating Neoadjuvant and Perioperative Treatment Strategies in Early Stage NSCLC

EP: 4.Treatment Considerations for Neoadjuvant and Perioperative Therapy in ES NSCLC

EP: 5.Management of Borderline Resectable NSCLC

EP: 6.Management of Resectable Early Stage NSCLC with Actionable Mutations

EP: 7.Considerations for Combination of Adjuvant Chemotherapy and Targeted Therapy in Resectable ES NSCLC

EP: 8.Patient with Unresectable Stage IIIB EGFR-Mutant NSCLC with N2 Bulky Disease

EP: 9.Expert Perspectives on Patient Selection for cCRT and sCRT in Unresectable ES NSCLC

EP: 10.Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC

Latest Conference Coverage